rs622342 in <i>SLC22A1</i>, <i>CYP2C9</i>*2 and <i>CYP2C9</i>*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study

rs622342 in <i>SLC22A1</i>, <i>CYP2C9</i>*2 and <i>CYP2C9</i>*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study

Background and Objective: Since the treatment outcome with oral anti-diabetics differs between individuals, the objective of this study is to evaluate the significance of rs622342 in <i>SLC22A1</i>, <i>CYP2C9</i>*2 (rs1799853) and <i>CYP2C9</i>*3 (rs1057910) with...

Full description

Bibliographic Details
Main Authors: Khaled Naja, Ali Salami, Said El Shamieh, Rajaa Fakhoury
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Journal of Personalized Medicine
Subjects:
type 2 diabetes mellitus
single nucleotide polymorphisms
<i>SLC22A1</i>
<i>OCT1</i>
Online Access:https://www.mdpi.com/2075-4426/10/2/53

Internet

https://www.mdpi.com/2075-4426/10/2/53

Similar Items